
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis is facing some immediate financial risks due to delayed equipment purchases and supply constraints on their robotic catheter production, but their recent launch of the MAGiC robotic catheter and strong customer feedback indicate potential for future revenue growth in the second half of 2026 and beyond. Despite lower revenue forecasts for 2026, projected revenue and operating losses for the second half of the fiscal year have improved, suggesting a brighter outlook for the company's financial performance. The company also has a strong product portfolio and is expected to establish new programs in the current year, indicating potential for future revenue growth. As a result, the financial analyst has a positive outlook on Stereotaxis' stock.
Bears say
Stereotaxis is facing headwinds in its disposable business due to the winding down of its relationship with JNJ and ongoing manufacturing constraints for its newly approved MAGiC catheter. They are working to remedy these issues and reach production of 500 MAGiC catheters per month by year-end, but this may negatively impact their revenue in the short-term. Additionally, while the company remains confident in its sales pipeline for its new GenesisX system, they have not yet reached their goal of 5 placements by the end of the year. Despite a top-line miss in Q1, the company is still expecting full-year revenue of over $40 million, with a heavier weighting towards the back-half of the year.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares